Activity of cefiderocol (S ) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
|
|
- Walter Hancock
- 6 years ago
- Views:
Transcription
1 J Antimicrob Chemother 2017; 72: doi: /jac/dkx049 Advance Access publication 22 March 2017 Activity of cefiderocol (S ) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals Matthew E. Falagas 1 4 *, Tilemachos Skalidis 1,5, Konstantinos Z. Vardakas 1 3 and Nicholas J. Legakis 1,5 on behalf of the Hellenic Cefiderocol Study Group 1 Research Center of Infectious Diseases, Iaso Group Hospitals, Athens, Greece; 2 Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece; 3 Department of Medicine-Infectious Diseases, Iaso General Hospital, Iaso Group, Athens, Greece; 4 Department of Medicine, Tufts University School of Medicine, Boston, MA, USA; 5 Central Laboratories, Iaso Group Hospitals, Athens, Greece *Corresponding author. Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, Athens, Greece. Tel:! ; Fax:! ; m.falagas@aibs.gr Members of the Hellenic Cefiderocol Study Group are listed in the Acknowledgements. Received 21 September 2016; returned 9 January 2017; revised 20 January 2017; accepted 26 January 2017 Background: Cefiderocol (S ), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases. Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/ avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline. Broth microdilution plates were used to determine MICs. Results: In total 189 non-fermentative Gram-negative bacteria (107 Acinetobacter baumannii and 82 Pseudomonas aeruginosa) and 282 Enterobacteriaceae (including 244 Klebsiella pneumoniae, 14 Enterobacter cloacae and 11 Providencia stuartii) were studied. For both A. baumannii and P. aeruginosa the MIC 90 of cefiderocol was 0.5 mg/l. For K. pneumoniae, E. cloacae and P. stuartii the MIC 90 of cefiderocol was 1, 1 and 0.5 mg/l, respectively. Tigecycline was the second most active antibiotic, followed by colistin. Conclusions: Cefiderocol exhibited greater antimicrobial activity in vitro against carbapenem-resistant Gramnegative bacteria than comparator antibiotics. Introduction Infections due to MDR and XDR Gram-negative bacteria have become a global public health problem. 1,2 Owing to the lack of new antimicrobial agents, treatment has mainly focused on older antibiotics, primarily polymyxins and secondarily fosfomycin. 3 Neither colistin nor fosfomycin has received marketing approval in the modern era. Several new antibiotics are under development for MDR and XDR Gram-negative bacteria. 4 Among them, cefiderocol (S ) appears to have higher activity against MDR bacteria compared with older or upcoming antibiotics. 4 Cefiderocol is actively transported into the periplasmic space along with ferric iron, 5 binds mainly to PBP3 of Gram-negative bacteria and inhibits bacterial cell wall synthesis. 6 Cefiderocol is broadly stable to ESBLs and class A, B, C and D carbapenemases. 5,7 Published studies on the activity of cefiderocol against Gramnegative bacteria have not focused exclusively on carbapenemresistant bacteria. 5,8 We sought to investigate the in vitro antimicrobial activity of cefiderocol and that of commercially available comparator antibiotics against a collection of contemporary, clinical, carbapenem-resistant Gram-negative bacteria from inpatients from various Greek hospitals. Materials and methods Ethics The study was approved by the scientific board/ethics committee of Iaso Hospital. Isolates Non-duplicate carbapenem-resistant Gram-negative bacteria were collected from the microbiology departments of 18 Greek hospitals. Each hospital provided the available bacteria isolated over the last 7 years ( ). Isolates were transferred to the Research Center of Infectious VC The Author Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please journals.permissions@oup.com. 1704
2 Cefiderocol against carbapenem-resistant Gram-negative bacteria JAC Diseases of Iaso Hospital for further testing. All isolates were stored at 70 C before testing. MIC testing Frozen broth microdilution plates prepared by International Health Management Associates (IHMA; Schaumburg, IL, USA) were used to determine the MICs of cefiderocol and comparators (meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline). Cefiderocol was tested in iron-depleted CAMHB (ID-CAMHB), whereas comparators were tested in CAMHB according to current CLSI guidelines for broth microdilution testing and previously published methodology. 9,10 Plates with wells containing different concentrations of antibiotics and positive (ID-CAMHB and CAMHB) and negative control wells were stored at 70 C and thawed for 1 h before use. Plates were inoculated with a standardized suspension containing the bacterium under study and sealed. The plates were incubated for h at 35 Cinanon-CO 2 incubator. If strong growth was confirmed in both growth control wells, reading of the MICs could proceed. Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC and Klebsiella pneumoniae ATCC were the quality control strains used for each laboratory testing day. If the results for the ATCC quality control strains were outside the expected range recommended by the CLSI, the MIC test was repeated. The breakpoints for meropenem, ceftazidime, cefepime, aztreonam, amikacin and ciprofloxacin for all species were defined according to the CLSI (NB - the CLSI does not provide breakpoints for aztreonam for Acinetobacter baumannii). 11 Resistance to colistin for A. baumannii and P. aeruginosa was also defined according to CLSI criteria. Resistance to colistin and tigecycline for Enterobacteriaceae was defined according to EUCAST. 12 Results A total of 471 (445 meropenem resistant and 26 meropenem intermediate) isolates, collected from ICUs and wards of 18 Greek hospitals, were included [282 Enterobacteriaceae (244 K. pneumoniae,1 Klebsiella oxytoca,14enterobacter cloacae, 11 Providencia stuartii, 7 E. coli, 4 Proteus mirabilis and 1 Serratia marcescens) and 189 non-fermentative Gram-negative bacteria (107 A. baumannii and 82 P. aeruginosa)]. Table 1 shows the summary data of the MIC range, MIC 50 and MIC 90 of the antibiotics for the tested bacterial isolates and their respective resistance percentages. The MIC range, MIC 50 and MIC 90 of cefiderocol for meropenem-resistant (,0.03 4, 0.5 and 1, respectively) and meropenem-intermediate (,0.03 1, 0.12 and 0.5 mg/l, respectively) isolates were slightly different. For all 471 isolates tested, regardless of species, cefiderocol had the lowest MIC 90 values among the 11 antibiotics. The highest MIC value of cefiderocol was 4 mg/l, seen in six isolates (five K. pneumoniae and one E. cloacae). These six isolates were all resistant to meropenem, five were resistant to amikacin and ciprofloxacin (the susceptible strain was E. cloacae), one to colistin (K. pneumoniae) and none to tigecycline. The MIC range of ceftolozane/tazobactam and ceftazidime/avibactam was 32 to.64 mg/l and 1 to.64 mg/l, respectively. The cefiderocol MICs for seven E. coli isolates ranged between 0.12 and 1 mg/l and those for four P. mirabilis ranged between 0.06 and 0.5 mg/l. The single S. marcescens had a cefiderocol MIC of 0.25 mg/l and that for K. oxytoca was 0.5 mg/l. Resistance to colistin was observed in 154 isolates [including: 4 inherently resistant P. mirabilis and 11 P. stuartii isolates; 91 K. pneumoniae isolates (37.2% of all K. pneumoniae), 1 with intermediate susceptibility; 45 A. baumannii isolates (42.1% of all A. baumannii); 1 P. aeruginosa isolate (1 additional isolate showed intermediate susceptibility); and 2 E. coli isolates]. The MIC range, MIC 50 and MIC 90 of cefiderocol did not differ between colistin-resistant and colistin-susceptible A. baumannii isolates (Table 2). Slightly higher MIC 50 values were observed for colistin-resistant K. pneumoniae strains (1 versus 0.5 mg/l for all strains; Table 2); the MIC 90 was the same (1 mg/l). A few K. pneumoniae isolates (25) exhibited either resistance or intermediate resistance to tigecycline. A similar cefiderocol MIC distribution was observed for tigecycline-resistant/intermediate and tigecycline-susceptible K. pneumoniae isolates (Table 2). All P. stuartii isolates were resistant/intermediate to tigecycline. Resistance or intermediate resistance to amikacin was observed for 258 isolates (100 A. baumannii, 1 E. coli, 94 K. pneumoniae, 49 P. aeruginosa, 3P. mirabilis and 11 P. stuartii). Cefiderocol s MIC 50 for amikacin-resistant/intermediate A. baumannii isolates was identical to that for amikacin-susceptible A. baumannii; themic 90 of cefiderocol was one dilution higher among amikacin-resistant/ intermediate A. baumannii (Table 2). Amikacin-resistant/ intermediate P. aeruginosa isolates had one dilution higher MIC 50 (0.12 and 0.06 mg/l) and MIC 90 (0.5 and 0.25 mg/l) values of cefiderocol compared with that of amikacin-susceptible P. aeruginosa. Amikacin-resistant K. pneumoniae isolates had one dilution higher MIC 50 (1 and 0.5 mg/l) and MIC 90 (2 and 1 mg/l) values of cefiderocol compared with amikacin-susceptible isolates. All P. stuartii isolates were resistant to amikacin. Discussion Cefiderocol had lower MICs than any of the 10 comparator antibiotics against a collection of contemporary, clinical, carbapenemnon-susceptible Gram-negative bacterial isolates. Cefiderocol showed potent antimicrobial activity with MIC 90 values 1 mg/l for all groups of organisms. The MIC 90 of cefiderocol was lower for non-fermenting Gram-negative bacteria than for Enterobacteriaceae. Minor differences in MIC values were seen according to specific resistance phenotypes. Overall, it seems that production of carbapenemases or other broad-spectrum b-lactamases is not a significant source of resistance to cefiderocol. The catalytic efficiency of VIM-2 carbapenemases for cefiderocol was very low in a recent study, while that of KPC carbapenemases could not be determined due to minimal hydrolysis. 7 Another study showed that NDM-1-producing strains (especially E. coli) had higher MICs of cefiderocol. 5 The reason for these elevated MICs for some strains is not clear, but the deficiency of iron-transport systems in P. aeruginosa strains implicated in other siderophore b-lactams is a possible consideration. 13 However, when these same strains of P. aeruginosa were tested under similar experimental conditions, cefiderocol did not demonstrate any discrepancy between in vitro activity and in vivo efficacy as the siderophore monobactams did. 14 A few isolates with higher maximum MIC values (.32 mg/l for A. baumannii, up to 8 mg/l for P. aeruginosa and.64 mg/l for Enterobacteriaceae) have been reported in other studies. 5,8 Nevertheless, the MIC 90 s of cefiderocol for all species were low and 1705
3 Falagas et al. Table 1. MIC range, MIC 50 and MIC 90 of tested antibiotics for carbapenem-resistant Gram-negative bacteria and resistance rates MIC (mg/l) Resistance (%) Species/antibiotic MIC range MIC 50 MIC 90 S I R A. baumannii (n"107) cefiderocol NA NA NA meropenem ceftazidime cefepime ceftazidime/avibactam NA NA NA ceftolozane/tazobactam NA NA NA aztreonam NA NA NA amikacin ciprofloxacin colistin tigecycline NA NA NA P. aeruginosa (n"82) cefiderocol NA NA NA meropenem ceftazidime cefepime ceftazidime/avibactam NA NA NA ceftolozane/tazobactam NA NA NA aztreonam amikacin ciprofloxacin colistin tigecycline NA NA NA K. pneumoniae (n"244) cefiderocol NA NA NA meropenem ceftazidime cefepime ceftazidime/avibactam NA NA NA ceftolozane/tazobactam NA NA NA aztreonam amikacin ciprofloxacin colistin tigecycline E. cloacae (n"14) cefiderocol NA NA NA meropenem ceftazidime cefepime ceftazidime/avibactam NA NA NA ceftolozane/tazobactam NA NA NA aztreonam amikacin 4 8, ciprofloxacin colistin tigecycline Continued 1706
4 Cefiderocol against carbapenem-resistant Gram-negative bacteria JAC Table 1 Continued MIC (mg/l) Resistance (%) Species/antibiotic MIC range MIC 50 MIC 90 S I R P. stuartii (n"11) cefiderocol NA NA NA meropenem ceftazidime cefepime ceftazidime/avibactam NA NA NA ceftolozane/tazobactam NA NA NA aztreonam amikacin ciprofloxacin colistin.8 a tigecycline S, susceptible; I, intermediate resistant; R, resistant; NA, not applicable. a All isolates had MIC.8 mg/l. Table 2. Comparison of cefiderocol MIC values (mg/l) between antibiotic-resistant and antibiotic-susceptible isolates Species MIC 50 MIC 90 MIC 50 MIC 90 colistin resistant colistin susceptible A. baumannii 0.06 (n"45) 0.5 (n"45) 0.06 (n"62) 0.5 (n"62) K. pneumoniae 1(n"91) 1 (n"91) 0.5 (n"153) 1 (n"153) tigecycline resistant/intermediate (n"25) tigecycline susceptible (n"219) K. pneumoniae amikacin resistant/intermediate amikacin susceptible A. baumannii 0.06 (n"100) 0.5 (n"100) 0.06 (n"7) 0.25 (n"7) K. pneumoniae 1(n"94) 2 (n"94) 0.5 (n"150) 1 (n"150) P. aeruginosa 0.12 (n"49) 0.5 (n"49) 0.06 (n"33) 0.25 (n"33) similar to those observed in this study. A different method for preparing iron-depleted media was utilized in these publications and therefore the studies are not directly comparable. This study used the currently approved method with ID-CAMHB. 9 In this collection of carbapenem-resistant isolates, resistance to colistin and amikacin was 32.7% and 54.8%, respectively. The second most active antibiotic was tigecycline. However, tigecycline s clinical utility is limited by several factors. First, it is not active against P. aeruginosa and its activity against A. baumannii is variable. 15 Second, tigecycline is approved for community-acquired pneumonia, intra-abdominal infections and skin infections only. Tigecycline may not be the best option for treatment of patients with bacteraemia, hospital- or ventilator-associated pneumonia and urinary tract infections (UTIs) that constitute the majority of nosocomial infections. 16 Finally, the approved dosing recommendations for infections due to susceptible bacteria may not be adequate to treat MDR/XDR bacteria. 17 Cefiderocol is currently in late-stage clinical development for complicated UTIs and carbapenem-resistant infections (NCT and NCT ). Based on Phase 1 pharmacokinetic exposures and Monte Carlo simulations, cefiderocol has a 90% probability of achieving ft.mic of 75% for an organism with an MIC of 4 mg/l, which was the highest MIC observed in this study. 18 Although the administration of piperacillin/tazobactam and carbapenems was associated with lower mortality, 19 cephalosporins did not consistently demonstrate better clinical outcomes when administered as prolonged infusions, but their in vivo efficacy is determined by the T.MIC principle as with other b-lactams. 20 In conclusion, cefiderocol exhibited potent antimicrobial activity in vitro against carbapenem-resistant Gram-negative bacteria, including colistin- and aminoglycoside-resistant strains. This activity did not seem to be significantly affected by specific resistance phenotypes. Thus, cefiderocol could be considered as a promising 1707
5 Falagas et al. candidate for the treatment of patients with infections due to carbapenem-resistant Gram-negative bacteria. Acknowledgements Members of the Hellenic Cefiderocol Study Group Dr S. Tsiplakou and Dr V. Papaioannou ( KAT General Hospital, Athens); Dr E. Trikka-Graphakos, Dr N. Charalampakis and Dr C. Sereti ( Thriassio General Hospital, Athens); Dr E. Lebessi and Dr E. Bozavoutoglou ( Aglaia Kyriakou Children s Hospital, Athens); Dr E. Vogiatzakis and Dr H. Moraiti ( Sotiria General Hospital, Athens); Dr A. Xanthaki and Dr M. Toutouza ( Ippokratio General Hospital, Athens); Dr K. Fountoulis, Dr E. Perivolioti, Dr H. Kraniotaki and Dr M. Bournia ( Evagelismos General Hospital, Athens); Dr S. Vourli ( Attikon General Hospital, Athens); Dr E. Peteinaki (General University Hospital, Larissa); Dr S. Chatzipanagiotou and Dr A. Ioannidis ( Aiginitio Hospital, Athens); Dr A. Makri, Dr M. Daskalaki and Dr E. Staikou ( Paidon Pentelis Children s Hospital, Athens); Dr K. Tzannetou and Dr H. Prifti ( Alexandra General Hospital, Athens); Dr K. Mentessidou ( Filoktitis Recovery and Rehabilitation Center, Athens); Dr A. Maltezou ( Euromedica Group, Athens); Dr E. Platsouka ( Agia Olga General Hospital, Athens); Dr N. Skarmoutsou ( Sismanogleio General Hospital, Athens); Dr I. Spiliopoulou and Dr M. Christofidou (University Hospital, Patras); Dr M. Falagas, Dr K. Vardakas, Dr N. Triarides and Dr N. Legakis ( Iaso General Hospital, Athens); Dr N. Legakis and Dr T. Skalidis ( Iaso General, Maternity and Gynecology Hospital, Athens); Dr M. Falagas and M. Kyriakidou (Alfa Institute of Biomedical Sciences, Athens). Funding This study was supported by Shionogi & Co., Ltd. Transparency declarations M. E. F. participated in advisory boards for Achaogen, AstraZeneca, Infectopharm, Tetraphase, Pfizer, Shionogi and Xellia; received lecture honoraria from Cipla, Merck, Sanofi and Novartis; and received research support from Angelini, Astellas, Rokitan and Shionogi. The remaining authors have nothing to declare. References 1 Falagas ME, Tansarli GS, Karageorgopoulos DE et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014; 20: Vardakas KZ, Rafailidis PI, Konstantelias AA et al. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? JInfect2013; 66: Falagas ME, Vouloumanou EK, Samonis G et al. Fosfomycin.Clin Microbiol Rev 2016; 29: Falagas ME, Mavroudis AD, Vardakas KZ. The antibiotic pipeline for multidrug resistant gram negative bacteria: what can we expect? Expert Rev Anti Infect Ther 2016; 14: Kohira N, West J, Ito A et al. In vitro antimicrobial activity of a siderophore cephalosporin, S , against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 2015; 60: Ito A, Nishikawa T, Oota M et al. S , a novel siderophore cephalosporin: binding affinity to PBP and bactericidal activity. In: Abstracts of the Twenty-fifth European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, Abstract European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland. 7 Ito-Horiyama T, Ishii Y, Ito A et al. Stability of novel siderophore cephalosporin S against clinically relevant carbapenemases. Antimicrob Agents Chemother 2016; 60: Ito A, Kohira N, Bouchillon SK et al. In vitro antimicrobial activity of S , a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 2016; 71: Tsuji M, Nakamura R, Hackel M et al. Use of iron-depleted cation-adjusted Mueller Hinton broth (ID-CAMHB) for microdilution testing of S , a novel siderophore cephalosporin. In: Abstracts of the Twenty-sixth European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, The Netherlands, Abstract P0808. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland. 10 Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Tenth Edition: Approved Standard M07-A10.CLSI,Wayne,PA,USA, Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fifth Informational Supplement M100-S25. CLSI, Wayne, PA, USA, EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 6.0, files/breakpoint_tables/v_6.0_breakpoint_table.pdf. 13 Ferguson AD, Deisenhofer J. Metal import through microbial membranes. Cell 2004; 116: Ghazi IM, Tsuji M, Nicolau DP. Activity of S siderophore cephalosporin and comparators against Pseudomonas aeruginosa in murine thigh infection model. In: Abstracts of Microbe 2016, Boston, MA, USA. Abstract Pournaras S, Koumaki V, Gennimata V et al. In vitro activity of tigecycline against Acinetobacter baumannii: global epidemiology and resistance mechanisms. Adv Exp Med Biol 2016; 897: Vardakas KZ, Rafailidis PI, Falagas ME. Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis 2012; 54: Falagas ME, Vardakas KZ, Tsiveriotis KP et al. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 2014; 44: Tsuji M, Singley C, Horiyama T et al. S , a novel siderophore cephalosporin: efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 gram dose with 1 hour and 3 hours infusion. In: Abstracts of IDWeek 2014, Philadelphia, PA, USA. Abstract Falagas ME, Tansarli GS, Ikawa K et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56: Korbila IP, Tansarli GS, Karageorgopoulos DE et al. Extendedorcontinuous versus short-term intravenous infusion of cephalosporins: a meta-analysis. Expert Rev Anti Infect Ther 2013; 11:
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationMichael Hombach*, Guido V. Bloemberg and Erik C. Böttger
J Antimicrob Chemother 2012; 67: 622 632 doi:10.1093/jac/dkr524 Advance Access publication 13 December 2011 Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationSamantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center
Samantha Trumm, Pharm.D. PGY-1 Resident Avera McKennan Hospital and University Center I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationcrossm Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-negative pathogens between
RESEARCH ARTICLE Clinical Science and Epidemiology crossm Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline
More informationBreaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationAddressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum
Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broadspectrum activity against Class A, C and D enzymes Alita Miller, PhD
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
More informationon April 8, 2018 by guest
AAC Accepted Manuscript Posted Online 9 January 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.02252-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 4 Antimicrobial
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationDetection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from a Tertiary Care Centre, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 12 (2015) pp. 578-583 http://www.ijcmas.com Original Research Article Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationBreakthrough medicines targeting the growing global health threat of antibiotic resistance. Jefferies Healthcare Conference June 2017
Breakthrough medicines targeting the growing global health threat of antibiotic resistance Jefferies Healthcare Conference June 2017 June 2017 Our Mission To build an enduring biopharmaceutical company
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationActivity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City
Journal of Antimicrobial Chemotherapy Advance Access published July 31, 2010 J Antimicrob Chemother doi:10.1093/jac/dkq278 Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationAntibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
NEW MICROBIOLOGICA, 34, 291-298, 2011 Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units Vladimíra Vojtová 1, Milan Kolář 2, Kristýna Hricová 2, Radek Uvízl 3, Jan Neiser
More informationCombating Drug-Resistant Infections Globally. Company Presentation
Combating Drug-Resistant Infections Globally Company Presentation Forward-Looking Statements and Other Important Cautions Any statement in this presentation about our future expectations, plans and prospects,
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationDetecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP)
Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationORIGINAL ARTICLE ABSTRACT
ORIGINAL ARTICLE Increasing prevalence of extended-spectrum-betalactamase among Gram-negative bacilli in Latin America 28 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Authors
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationPresenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update
Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's
More informationDetection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary Care Hospital in North India
Original Article Vol. 25 No. 3 Ampc β-lactamase Production in Gram-Negative Bacilli:-Chaudhary U, et al. 129 Detection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary
More informationSummary of unmet need guidance and statistical challenges
Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationReceived: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008
J Microbiol Immunol Infect. 29;42:317-323 In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center
More informationDr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center,
Dr Vivien CHUANG Associate Consultant Infection Control Branch, Centre for Health Protection/ Infectious Disease Control and Training Center, Hospital Authority NDM-1, which stands for New Delhi Metallo-beta-lactamase-1
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationPrinciples and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013
Principles and Practice of Antimicrobial Susceptibility Testing Microbiology Technical Workshop 25 th September 2013 Scope History Why Perform Antimicrobial Susceptibility Testing? How to Perform an Antimicrobial
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationThe discovery of antibiotics heralded
New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms Troy Kish, PharmD, BCPS The discovery of s heralded a new era of medicine; however, the curtain is beginning to draw on this
More informationHelen Heffernan. Rosemary Woodhouse
ANTIMICROBIAL RESISTANCE AMONG GRAM-NEGATIVE BACILLI FROM BACTERAEMIA, 2007 Helen Heffernan Rosemary Woodhouse Antibiotic Reference Laboratory Communicable Disease Group Institute of Environmental Science
More informationEUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM)
EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM) Christian G. Giske, MD/PhD Chairman of ESDReM Karolinska University Hospital and EUCAST ECCMID, 22 maj 2013 The background Guidance on
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationProtocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland
Protocol for Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland Version 1.0 23 December 2011 General enquiries and contact details This is the first version (1.0) of the Protocol
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationFluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results,
74 The Open Microbiology Journal, 2012, 6, 74-78 Open Access Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results, 2009-2010 Sam Bouchillon 1*, Daryl J.
More informationOvernight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients
TABLE 1. Origin and carbapenem resistance characteristics of the 64 Acinetobacter baumannii stock D-750 Overnight identification of imipenem-resistant Acinetobacter baumannii carriage in hospitalized patients
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationPharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens
Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Jared L. Crandon, Pharm.D., BCPS Associate Director, Clinical and Experimental Pharmacology Center for Anti-Infective Research
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationVersion 1.01 (01/10/2016)
CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationAntibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationHospital ID: 831. Bourguiba Hospital. Tertiary hospital
Global Point Prevalence Survey of Antimicrobial Consumption and Resistance in hospitals worldwide Hospital ID: 831 Habib Bourguiba Hospital Tertiary hospital Tunisia Point Prevalence Survey Habib 2017
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More information